Home › Funds › DAFNA Capital Management LLC › NGNE

DAFNA Capital Management LLC position in NGNE

NEUROGENE INC · Health Care

DAFNA Capital Management LLC reported holding 150,532 shares of NGNE (NEUROGENE INC) in its Q3 2026 13F filing — a position valued at US$4.2M, representing 0.89% of its reported portfolio and ranking #25 among its reported holdings. DAFNA Capital Management LLC has disclosed NGNE holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)150.53K sh
Reported value held$4.19M
Portfolio Weight0.89%
First reportedQ2 2024
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How DAFNA Capital Management LLC's NGNE position evolved

DAFNA Capital Management LLC first disclosed a stake in NGNE in Q2 2024 at 11,000 shares (US$400K). The position peaked in Q3 2026 at 150,532 shares, worth US$4.2M. Across 10 filings, DAFNA Capital Management LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 150,532 shares valued at US$4.2M — an increase of 61,500 shares quarter over quarter.. Notable position changes include a 562% increase in Q4 2024 (shares fell 49% over the following quarter), a 102% increase in Q1 2026 (shares rose 56% over the following quarter), a 69% increase in Q3 2026 (shares fell 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 11.00K $400.29K New
Q3 2024 7.78K $326.24K Reduce
Q4 2024 51.50K $1.18M Add
Q1 2025 51.50K $603.07K Hold
Q2 2025 51.10K $763.88K Reduce
Q3 2025 30.38K $526.40K Reduce
Q4 2025 27.97K $576.26K Reduce
Q1 2026 56.63K $1.14M Add
Q2 2026 89.03K $2.80M Add
Q3 2026 150.53K $4.19M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NGNE and 13F data

NGNE (NEUROGENE INC) is a Health Care company. 41 other funds we track also report a position in NGNE — the largest reported positions include Samsara BioCapital, LLC (US$51.9M), Casdin Capital (US$44.1M), Redmile Group, LLC (US$43.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NGNE

All NGNE fund holders →

FAQ

How long has DAFNA Capital Management LLC held NGNE?

DAFNA Capital Management LLC has disclosed NGNE holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is DAFNA Capital Management LLC's current position in NGNE?

As of Q3 2026, DAFNA Capital Management LLC holds 150.53K shares of NGNE (NEUROGENE INC), valued at $4.19M, representing 0.89% of its reported portfolio and ranking #25.

Has DAFNA Capital Management LLC been buying or selling NGNE?

In the latest 13F filing (Q3 2026), DAFNA Capital Management LLC increased its position in NGNE. The position peaked in Q3 2026 at 150.53K shares.

Which other funds hold NGNE?

Other major institutional holders of NGNE include Samsara BioCapital, LLC, Casdin Capital, Redmile Group, LLC, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.